Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2017 criteria, including lumbar puncture. At the time of diagnosis RRMS is classified as active or highly active based on the relapse rate and magnetic resonance imaging findings. For active RRMS, interferon-β, dimethyl fumarate, glatiramer acetate, ocrelizumab and teriflunomide are recommended treatments. For highly active disease, whether on previous immunomodulating drug treatment or not, alemtuzumab, cladribine, fingolimod, natalizumab or ocrelizumab are recommended. Ocrelizumab may also be used for primary progressive MS. Rehabilitation should be considered at every phase of the disease.
Anne Remes (Chair)